Lenz Therapeutics
Manufacturing · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
201 Lomas Santa Fe Dr Ste 300, Solana Be...Phone Number
(858) 925-7000Website
www.lenz-tx.comRevenue
$21 MillionStock Symbol
LENZIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Lenz Therapeutics
LENZ Therapeutics is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision. The companys lead program is an aceclidine based eye drop designed to restore the loss of near vision associated with presbyopia.Explore more
Lenz Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Lenz Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Lenz Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Lenz Therapeutics has new funding data
Check out if Lenz Therapeutics is spiking on competitors!
Click to see if Lenz Therapeutics had a recent Job posting/layoffs
Lenz Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Lenz Therapeutics
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Lenz Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Lenz Therapeutics launches new products
Recommended Actions
Find VP level buyers at Lenz Therapeutics
Find more new buyers
Compare Similar Companies to Lenz Therapeutics
Compare insights from companies similar to Lenz Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Lenz Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Lenz Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Lenz Therapeutics.
Lenz Therapeutics financials insights
Gather financial insights about Lenz Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$47M
2022
Private Equity
$10M
2023
Series B
$83.5M
2024
Share Placement
$30M
Lenz Therapeutics Tech Stack
A closer look at the technologies used by Lenz Therapeutics
Most Recent Scoops
Person-Based
Pharmaceuticals
Person-Based
Product Marketing
Person-Based
Earnings, Research & Development, Finance
Person-Based
Product Marketing, Corporate Strategy
Person-Based
Earnings, Finance
Lenz Therapeutics News & Media
LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia
VIZZ is now available for those who qualify through a convenient telehealth platform in addition to existing access through eye care professionalsLENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand
LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New ZealandLENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China
The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027 The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027LENZ Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults, today announced that company management will participate in the following upcoming investor conferences:
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Lenz Therapeutics
Sign Up For FreeTo access detailed company insights
LENZ Therapeutics is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision. The companys lead program is an aceclidine based eye drop designed to restore the loss of near vision associated with presbyopia.... Read More
